Nicolas Duployez
Overview
Explore the profile of Nicolas Duployez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
114
Citations
1240
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Simon L, Caulier A, Berthon C, Boyer T, Harrivel V, Joris M, et al.
Curr Res Transl Med
. 2025 Feb;
73(2):103500.
PMID: 39947092
Older adults with acute myeloid leukemia (AML) have a poor prognosis because frailty and the characteristics of the disease limit the use of intensive chemotherapy (ICT). Treatment with 5-azacitidine (5-AZA)...
2.
Ernst M, Versluis J, Valk P, Bierings M, Tamminga R, Hooimeijer L, et al.
Hemasphere
. 2025 Jan;
9(1):e70057.
PMID: 39822584
Familial Platelet Disorder with associated Myeloid Malignancy (FPDMM, FPD/AML, -FPD), caused by monoallelic deleterious germline variants, is characterized by bleeding diathesis and predisposition for hematologic malignancies, particularly myelodysplastic syndrome (MDS)...
3.
Tiso F, In t Hout F, Knops R, Kroeze L, van Rooij A, van de Loosdrecht A, et al.
Hemasphere
. 2025 Jan;
9(1):e70034.
PMID: 39760001
No abstract available.
4.
Tregnago C, Benetton M, Ries R, Peplinski J, Alonzo T, Stirewalt D, et al.
J Clin Oncol
. 2024 Dec;
43(8):972-984.
PMID: 39621969
Purpose: Several genomic subsets of mutations with varying sequences (type A, B, D, etc) have been identified. Despite molecular heterogeneity, mutations cumulatively portend a more favorable outcome, but biology and...
5.
Joudinaud R, Boudry A, Fenwarth L, Geffroy S, Salson M, Dombret H, et al.
Blood Adv
. 2024 Oct;
9(2):365-374.
PMID: 39418643
Despite the use of midostaurin (MIDO) with intensive chemotherapy (ICT) as frontline treatment for Fms-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia (AML), complete remission rates are close to 60%...
6.
Interactions between eosinophils and IL-5Rα-positive mast cells in nonadvanced systemic mastocytosis
Lefevre G, Gibier J, Bongiovanni A, Lhermitte L, Rossignol J, Anglo E, et al.
J Allergy Clin Immunol
. 2024 Aug;
154(6):1523-1533.
PMID: 39151478
Background: Bidirectional interactions between eosinophils and mast cells (MCs) have been reported in various allergic diseases. Bone marrow (BM) eosinophilia, and to a lesser extent blood eosinophilia, is common in...
7.
Duployez N, Preudhomme C
Br J Haematol
. 2024 Jun;
205(3):772-779.
PMID: 38934371
The ongoing or anticipated therapeutic advances as well as previous experience in other malignancies, including acute myeloid leukaemia, have made molecular monitoring a potential interesting tool for predicting outcomes and...
8.
9.
Hirsch P, Lambert J, Bucci M, Deswarte C, Boudry A, Lambert J, et al.
Blood Cancer J
. 2024 Jun;
14(1):97.
PMID: 38871702
The evaluation of measurable residual disease (MRD) in acute myeloid leukemia (AML) using comprehensive mutation analysis by next-generation sequencing (NGS) has been investigated in several studies. However controversial results exist...
10.
Ragnarsson C, Yang M, Moura-Castro L, Aydin E, Gunnarsson R, Olsson-Arvidsson L, et al.
Genes Chromosomes Cancer
. 2024 May;
63(5):e23242.
PMID: 38738968
Constitutional polymorphisms in ARID5B are associated with an increased risk of developing high hyperdiploid (HeH; 51-67 chromosomes) pediatric B-cell precursor acute lymphoblastic leukemia (BCP ALL). Here, we investigated constitutional and...